A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease

British Journal of Clinical Pharmacology
C D BindeM Klemp

Abstract

To the best of our knowledge, there are no systematic reviews or meta-analyses that compare rasagiline, selegiline and safinamide. Therefore, we aimed to perform a drug class review comparing all available monoamine oxidase type B (MAO-B) inhibitors in a multiple treatment comparison. We performed a systematic literature search to identify randomized controlled trials assessing the efficacy of MAO-B inhibitors in patients with Parkinson's disease. MAO-B inhibitors were evaluated either as monotherapy or in combination with levodopa or dopamine agonists. Endpoints of interest were change in the Unified Parkinson's Disease Rating Scale (UPDRS) score and serious adverse events. We estimated the relative effect of each MAO-B inhibitor versus the comparator drug by creating three networks of direct and indirect comparisons. For each of the networks, we considered a joint model. The systematic literature search and study selection process identified 27 publications eligible for our three network analyses. We found the relative effects of rasagiline, safinamide and selegiline treatment given alone and compared to placebo in a model without explanatory variables to be 1.560 (1.409, 1.734), 1.449 (0.873, 2.413) and 1.532 (1.337, 1.757) ...Continue Reading

References

Nov 16, 1989·The New England Journal of Medicine·UNKNOWN Parkinson Study Group
Nov 1, 1995·Annals of Neurology·C W OlanowJ Esterlitz
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·H AllainH C Neukirch
Dec 1, 1995·Journal of the Neurological Sciences·J MallyT W Stone
Aug 24, 1999·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J P LarsenJ E Erdal
Dec 21, 2002·Archives of Neurology·UNKNOWN Parkinson Study Group
Aug 10, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Matthew B SternC Warren Olanow
Aug 25, 2004·Neurology·F StocchiUNKNOWN Safinamide Parkinson's Study Group
Mar 17, 2006·Neurology·S PålhagenUNKNOWN Swedish Parkinson Study Group
May 23, 2006·Lancet Neurology·Lonneke M L de Lau, Monique M B Breteler
Sep 25, 2009·The New England Journal of Medicine·C Warren OlanowUNKNOWN ADAGIO Study Investigators
Apr 19, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Hasmet A HanagasiMurat Emre
Jun 1, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Olivier RascolWerner Poewe
Sep 14, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Fabrizio StocchiUNKNOWN Study 015 Investigators
Sep 13, 2012·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A H V SchapiraUNKNOWN Study 017 Investigators
Dec 11, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Rupam BorgohainUNKNOWN Study 016 Investigators
Jun 13, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Robert A HauserUNKNOWN ANDANTE study investigators
Jul 22, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Rupam BorgohainUNKNOWN Study 018 Investigators
Dec 17, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·C Warren Olanow
Dec 21, 2014·BMJ : British Medical Journal·Christopher G Goetz, Gian Pal
May 13, 2015·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·P BaroneM Tinazzi
Jul 15, 2015·CNS Drugs·Daphne Robakis, Stanley Fahn
Jan 6, 2016·Expert Review of Pharmacoeconomics & Outcomes Research·Maribel Márquez-CruzMayela Rodríguez-Violante
Jan 16, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Thien Thien LimHubert H Fernandez
Nov 11, 2016·The Journal of Neuropsychiatry and Clinical Neurosciences·Laura L Frakey, Joseph H Friedman
Dec 3, 2016·Journal of Parkinson's Disease·Robert A HauserUNKNOWN NINDS NET-PD Investigators
May 12, 2017·Neurology·Fabrizio StocchiUNKNOWN Preladenant Early Parkinson Disease Study Group
Mar 24, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Susan H FoxUNKNOWN Movement Disorder Society Evidence-Based Medicine Committee

❮ Previous
Next ❯

Citations

Dec 21, 2018·Drug and Therapeutics Bulletin
Feb 1, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Paolo GuglielmiJacobus P Petzer
Nov 30, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Isabella BologninoMarco Catto
Sep 29, 2019·Journal of Neural Transmission·Tamás TábiÉva Szökő
Nov 17, 2020·Frontiers in Cellular and Infection Microbiology·Jing LiuLei Shao
Jan 16, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Alisa A NevskayaCosimo D Altomare
Mar 7, 2021·Clinical Drug Investigation·Riccardo GiossiFrancesco Scaglione
Apr 16, 2021·Journal of Medicinal Chemistry·Elisa SassettiLuca Laraia
Jul 30, 2021·Journal of Neural Transmission·J KoschelW H Jost
Oct 2, 2021·Expert Opinion on Drug Safety·Kanako KuriharaYoshio Tsuboi
Feb 3, 2022·Journal of Neural Transmission·Wolfgang H Jost

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.